1311138-07-4

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 19217-50-6 4-methyl-3-(methyloxy)phenol 
• 13120-77-9 2-methyl-5-nitroanisole 
• 16452-01-0 ortho-cresidine 
• 1311138-06-3 2-{[4-methyl-3-(methyloxy)phenyl]oxy}-5-nitropyridine 

Downstream Products

• 1311138-54-1 1,1-dimethylethyl (1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}cyclobutyl)carbamate 
• 1311138-52-9 1,1-dimethylethyl ((1R)-1-methyl-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-25-6 1,1-dimethylethyl ((1S)-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-08-5 1,1-dimethylethyl {(1R)-1-methyl-2-[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]-2-oxoethyl}carbamate 
• 1311138-22-3 1,1-dimethylethyl ((1R)-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-50-7 1,1-dimethylethyl ((1R)-2,2-dimethyl-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-26-7 (2S)-2-amino-N-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)butanamide 
• 1311138-51-8 3-methyl-N'-(6-{[4-methyll-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-D-valinamide 
• 1311138-55-2 1-amino-N-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)cyclobutanecarboxamide 
• 1311136-80-7 (5R)-5-methyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}3-pyridinyl)-2,4-imidazolidinedione 
• 1311136-84-1 (5R)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione 
• 1311136-86-3 (5S)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione 
• 1311136-95-4 (5R)-5-(1-methylethyl)-3-(4-{[4-methyl-3-(methyloxy)phenyl]oxy}phenyl)-2,4-imidazolidinedione 
• 1311136-98-7 (5R)-5-(1,1-dimethylethyl)-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione 

Relevant academic research and scientific papers

KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, Y1 to Y4 and R1 to R6 are as described herein.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

IMIDAZOLIDINEDIONE DERIVATIVES

The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.